Beyond Air Inc

Research Beyond Air Inc (XAIR) on Bullrun: market cap USD 2.94M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 2.94M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 3.71M-USD 46.63M-USD 44.10M-44.9%-0.69USD 4.67MUSD 23.59MUSD 13.58M
FY2024USD 1.16M-USD 60.24M-USD 61.76M-112.8%-1.82USD 11.38MUSD 17.50MUSD 25.05M
FY2023n/a-USD 55.82M-USD 36.89Mn/a-1.86USD 29.16MUSD 200.00KUSD 37.92M
FY2022n/a-USD 43.18M-USD 24.51Mn/an/aUSD 80.24MUSD 200.00KUSD 72.70M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 2.94Mn/an/an/a
20252025-12-31USD 3.39Mn/an/an/a
20242024-12-31USD 26.68Mn/an/an/a
20232023-12-29USD 62.67Mn/an/an/a
20222022-12-30USD 194.13Mn/an/an/a
20212021-12-31USD 265.85Mn/an/an/a

About Beyond Air Inc

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM).

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Beyond Air Inc's market cap?

Beyond Air Inc's market capitalization is USD 2.94M.

What does Beyond Air Inc do?

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM).